TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07818629: A Single Center, Single-Blind, Randomized, Dose-Escalation, Placebo-Controlled, Multiple Dose, Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of INT101 Intramuscular Injection in Healthy Adults

Sponsor: InThera Inc. Korea · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 30 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,507,200

Rescue Site Savings

+$4,950,060

Unlock Full NCT07818629 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07818629 Rescue Dossier →